Congo vs Mongolia: Access to anti-retroviral drugs, male
Congo
40.0%
in 2024
Mongolia
42.0%
in 2024
Congo rank
131st
Mongolia rank
128th
Access to anti-retroviral drugs, male over time
- Congo
- Mongolia
How they compare
Mongolia currently reports 42.0% against 40.0% in Congo, a difference of 2.0%.
That makes Mongolia's figure about 1.1 times Congo's.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Mongolia ahead.
Congo ranks 131st and Mongolia ranks 128th of 141 countries.
Across the 3 decades both report, Congo averaged higher in 1 and Mongolia in 2.
Head to head by decade
| Decade | Congo | Mongolia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 4.9% | 0.7% | 4.2% | Congo |
| 2010s | 20.4% | 22.9% | 2.5% | Mongolia |
| 2020s | 31.8% | 38.8% | 7.0% | Mongolia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Congo or Mongolia?
- Mongolia, at 42.0% against 40.0% in Congo as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Congo and Mongolia?
- 2.0%, with Mongolia ahead.
- How many years of comparable data are there for Congo and Mongolia?
- 25 years are reported by both, from 2000 to 2024.
- How do Congo and Mongolia rank globally for access to anti-retroviral drugs, male?
- Congo ranks 131st and Mongolia ranks 128th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.